PL3848027T3 - Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego - Google Patents

Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego

Info

Publication number
PL3848027T3
PL3848027T3 PL21158231.7T PL21158231T PL3848027T3 PL 3848027 T3 PL3848027 T3 PL 3848027T3 PL 21158231 T PL21158231 T PL 21158231T PL 3848027 T3 PL3848027 T3 PL 3848027T3
Authority
PL
Poland
Prior art keywords
receptor modulators
glucocorticoid receptor
fused azadecalin
octahydro fused
azadecalin glucocorticoid
Prior art date
Application number
PL21158231.7T
Other languages
English (en)
Inventor
Hazel Hunt
Iain Walters
Benoit GOURDET
Original Assignee
Corcept Therapeutics Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Incorporated filed Critical Corcept Therapeutics Incorporated
Publication of PL3848027T3 publication Critical patent/PL3848027T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL21158231.7T 2013-11-25 2014-11-21 Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego PL3848027T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361908333P 2013-11-25 2013-11-25
US201461985035P 2014-04-28 2014-04-28

Publications (1)

Publication Number Publication Date
PL3848027T3 true PL3848027T3 (pl) 2023-07-24

Family

ID=53180165

Family Applications (3)

Application Number Title Priority Date Filing Date
PL19177963T PL3560493T3 (pl) 2013-11-25 2014-11-21 Skondensowane oktahydroazadekaliny będące modulatorami receptora glukokortykoidowego
PL21158231.7T PL3848027T3 (pl) 2013-11-25 2014-11-21 Skondensowane oktahydrozwiązki azadekaliny jako modulatory receptora glukokortykoidowego
PL14863514T PL3074011T3 (pl) 2013-11-25 2014-11-21 Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19177963T PL3560493T3 (pl) 2013-11-25 2014-11-21 Skondensowane oktahydroazadekaliny będące modulatorami receptora glukokortykoidowego

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14863514T PL3074011T3 (pl) 2013-11-25 2014-11-21 Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego

Country Status (20)

Country Link
US (7) US10047082B2 (pl)
EP (4) EP3848027B1 (pl)
JP (5) JP6516743B2 (pl)
KR (1) KR102352737B1 (pl)
CN (2) CN106029066B (pl)
AU (1) AU2014352915B2 (pl)
BR (1) BR112016011826B1 (pl)
CA (1) CA2931302C (pl)
DK (2) DK3848027T3 (pl)
ES (3) ES2943542T3 (pl)
FI (1) FI3848027T3 (pl)
IL (1) IL245848B (pl)
MX (1) MX368167B (pl)
MY (1) MY180141A (pl)
PH (1) PH12016500968B1 (pl)
PL (3) PL3560493T3 (pl)
PT (2) PT3848027T (pl)
RU (1) RU2674983C1 (pl)
WO (1) WO2015077530A1 (pl)
ZA (1) ZA201604026B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
CN106029066B (zh) * 2013-11-25 2019-03-15 科赛普特治疗公司 八氢稠合的氮杂萘烷糖皮质激素受体调节剂
CN107530339B (zh) 2015-03-30 2021-03-16 科赛普特治疗学股份有限公司 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全
EP3423453A4 (en) 2016-03-01 2019-11-06 Corcept Therapeutics, Inc. USE OF GLUCOCORTICOID RECEPTOR MODULATORS TO POTENTIATE CONTROL POINT INHIBITORS
CN106478464B (zh) * 2016-08-30 2018-06-05 黄河三角洲京博化工研究院有限公司 一种2-氟-6-三氟甲基苯磺酰氯的制备方法
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
WO2018165460A1 (en) 2017-03-09 2018-09-13 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
MX2019011543A (es) 2017-03-31 2019-12-16 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides para el tratamiento de cancer cervical.
WO2018209142A2 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
EP3641780A4 (en) 2017-06-20 2021-02-24 Corcept Therapeutics, Inc. TREATMENT METHODS OF NEURO-EPITHELIAL TUMORS USING SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS
US10494349B2 (en) 2018-04-23 2019-12-03 Corcept Therapeutics, Inc. Methods of preparing regioselective N-alkyl triazoles
US10981918B2 (en) 2018-07-20 2021-04-20 Grünenthal GmbH Further substituted triazolo quinoxaline derivatives
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
CN113194931B (zh) 2018-12-19 2023-11-10 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
JP2022523376A (ja) * 2019-02-22 2022-04-22 コーセプト セラピューティクス， インコーポレイテッド レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途
JP2023505948A (ja) 2019-12-11 2023-02-14 コーセプト セラピューティクス， インコーポレイテッド 抗精神病薬誘発性体重増加のミリコリラントによる治療方法
EP4076470A4 (en) * 2019-12-21 2023-11-22 Corcept Therapeutics Incorporated DIFFERENTIAL TREATMENT AND DIAGNOSIS BETWEEN ACTH-DEPENDENT CUSHING SYNDROME AND ACTH-INDEPENDENT CUSHING SYNDROME
IL298957A (en) 2020-06-22 2023-02-01 Corcept Therapeutics Inc Quaternary indazole glucocorticoid receptor antagonists
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
WO2022166810A1 (zh) * 2021-02-03 2022-08-11 江苏恒瑞医药股份有限公司 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS322220B1 (pl) 1954-11-30 1957-04-11
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
CA1270488A (en) 1983-09-26 1990-06-19 John M. Schaus Pyrazole-ring alkylated pyrazoloquinolines and intermediates
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
ES2173921T3 (es) 1993-08-06 2002-11-01 Glaxosmithkline Spa Derivados de hidroisoquinolina.
AU756983B2 (en) 1998-03-10 2003-01-30 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
AU2002355929A1 (en) 2001-07-17 2003-03-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
IL159913A0 (en) * 2001-07-23 2004-06-20 Corcept Therapeutics Inc Methods for preventing antipsychotic-induced weight gain
US6679935B2 (en) * 2001-08-14 2004-01-20 Apex Advanced Technologies, Llc Lubricant system for use in powdered metals
US6831093B2 (en) 2002-01-22 2004-12-14 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SG145716A1 (en) 2003-09-03 2008-09-29 Wyeth Corp Amorphous rapamycin 42-ester with 3-hydroxy-2- (hydroxymethyl)-2- methylpropionic acid and pharmaceutical compositions containing the same
JP4851345B2 (ja) 2004-01-09 2012-01-11 コーセプト セラピューティクス， インコーポレイテッド アザデカリン糖質コルチコイド受容体モジュレーター
NZ550362A (en) * 2004-03-09 2010-06-25 Corcept Therapeutics Inc Fused ring azadecalin glucocorticoid receptor modulators
AU2006232660B2 (en) * 2005-04-05 2010-03-25 F. Hoffmann-La Roche Ag 1H-Pyrazole 4-Carboxylamides, their preparation and their use as 11Beta-hydroxysteroid dehydrogenase
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
WO2009058944A2 (en) * 2007-11-01 2009-05-07 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
WO2009100171A1 (en) * 2008-02-07 2009-08-13 Bristol-Myers Squibb Company Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
CA2761255C (en) 2009-05-12 2017-05-09 Corcept Therapeutics, Inc. Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
WO2012027702A1 (en) 2010-08-27 2012-03-01 Corcept Therapeutics, Inc. Pyridyl-amine fused azadecalin modulators
WO2012094618A1 (en) 2011-01-07 2012-07-12 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT2854814T (pt) * 2012-05-25 2018-03-15 Corcept Therapeutics Inc Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona
CN106029066B (zh) 2013-11-25 2019-03-15 科赛普特治疗公司 八氢稠合的氮杂萘烷糖皮质激素受体调节剂
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer

Also Published As

Publication number Publication date
RU2016123449A (ru) 2017-12-28
US20190048004A1 (en) 2019-02-14
EP3074011B1 (en) 2019-07-24
AU2014352915A1 (en) 2016-06-30
BR112016011826B1 (pt) 2022-09-27
WO2015077530A1 (en) 2015-05-28
CN106029066B (zh) 2019-03-15
US20190135805A1 (en) 2019-05-09
EP3848027B1 (en) 2023-04-05
BR112016011826A2 (pl) 2017-08-08
PT3848027T (pt) 2023-05-11
EP3560493A1 (en) 2019-10-30
RU2674983C1 (ru) 2018-12-14
CN109761976A (zh) 2019-05-17
DK3848027T3 (da) 2023-05-01
MY180141A (en) 2020-11-23
EP3848027A1 (en) 2021-07-14
CA2931302A1 (en) 2015-05-28
NZ720969A (en) 2021-05-28
JP2019094355A (ja) 2019-06-20
US10047082B2 (en) 2018-08-14
EP3074011A1 (en) 2016-10-05
PH12016500968A1 (en) 2016-07-18
IL245848A0 (en) 2016-07-31
EP3074011A4 (en) 2017-05-31
MX2016006725A (es) 2016-09-09
CA2931302C (en) 2021-12-07
PH12016500968B1 (en) 2016-07-18
US10323034B2 (en) 2019-06-18
CN109761976B (zh) 2021-11-23
ES2943542T3 (es) 2023-06-14
DK3074011T3 (da) 2019-09-30
JP2016537394A (ja) 2016-12-01
ZA201604026B (en) 2019-03-27
US20230167111A1 (en) 2023-06-01
JP2021073315A (ja) 2021-05-13
PL3560493T3 (pl) 2021-10-04
KR20160089506A (ko) 2016-07-27
US20210139478A1 (en) 2021-05-13
EP3560493B1 (en) 2021-03-31
FI3848027T3 (fi) 2023-05-04
KR102352737B1 (ko) 2022-01-17
US20150148341A1 (en) 2015-05-28
ES2869172T3 (es) 2021-10-25
US10787449B2 (en) 2020-09-29
PL3074011T3 (pl) 2020-01-31
JP2018012734A (ja) 2018-01-25
US20200361935A1 (en) 2020-11-19
IL245848B (en) 2020-08-31
JP2023011052A (ja) 2023-01-20
US20190241563A1 (en) 2019-08-08
MX368167B (es) 2019-09-23
US11370789B2 (en) 2022-06-28
PT3074011T (pt) 2019-09-17
CN106029066A (zh) 2016-10-12
ES2743620T3 (es) 2020-02-20
EP4219494A1 (en) 2023-08-02
US11560379B2 (en) 2023-01-24
AU2014352915B2 (en) 2018-03-15
JP6516743B2 (ja) 2019-05-22

Similar Documents

Publication Publication Date Title
ZA201604026B (en) Octahydro fused azadecalin glucocorticoid receptor modulators
HK1250014B (zh) 雜芳基-酮稠合的氮萘烷糖皮質激素受體調節劑
IL247254A0 (en) Medical combinations with estrogen receptor modulators
HK1211923A1 (en) Polycyclic estrogen receptor modulators and uses thereof
HK1222177A1 (zh) 新型 受體調節劑
HK1223353A1 (zh) 受體調節劑
HK1209744A1 (en) Novel selective androgen receptor modulators
HK1218647A1 (zh) 血管加壓素- 受體激動劑
GB201320091D0 (en) Selective glucocorticoid receptor ligands
GB201301896D0 (en) Novel Estrogen Receptor Ligands